Stocks · News reference
First-in-class pan-RAS(ON) ADC is cleared for clinical developmentDesigned to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.IND submissions to U.S. FDA and China NMPA are in
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year. The company reported $13.056 million in sales
Read original at benzinga"Dosing the first U.S. patient with AN9025 on an intermittent weekly schedule is a significant milestone and advances our clinical strategy to evaluate AN9025 with a differentiated approach. We believe based on our
Read original at benzingaUS stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.
Read original at benzinga